# Acrivon Therapeutics, Inc.: Form 8-K, filed Oct 11, 2024

- Company: [Acrivon Therapeutics, Inc.](/companies/acrv.md) (CIK 1781174)
- Form: 8-K
- Filed: 2024-10-11
- Accepted by EDGAR: Oct 11, 2024, 08:00 ET
- Period: 2024-10-11
- Accession: 0000950170-24-114213
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/acrv-20241011.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/

## Items reported

- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1781174/000095017024114213/acrv-20241011.htm

Filed Oct 11, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-114213. Last ingested by Listed: Nov 6, 2026, 12:11 ET. No prices; not investment advice.